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Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Despite concerted
efforts to improve current therapies and develop novel clinical approaches, patient survival remains poor. As such,
increasing attention has focused on developing new therapeutic strategies that specifically target the apoptotic pathway in
order to improve treatment responses. Recently, nutlins, small-molecule antagonists of MDM2, have been developed to
inhibit p53-MDM2 interaction and activate p53 signaling in cancer cells. Glioma cell lines and primary cultured glioblastoma
cells were treated with nutlin-3a. Nutlin-3a induced p53-dependent G1- and G2-M cell cycle arrest and apoptosis in glioma
cell lines with normal TP53 status. In addition, nutlin-arrested glioma cells show morphological features of senescence and
persistent induction of p21 protein. Furthermore, senescence induced by nutlin-3a might be depending on mTOR pathway
activity. In wild-type TP53 primary cultured cells, exposure to nutlin-3a resulted in variable degrees of apoptosis as well as
cellular features of senescence. Nutlin-3a-induced apoptosis and senescence were firmly dependent on the presence of
functional p53, as revealed by the fact that glioblastoma cells with knockdown p53 with specific siRNA, or cells with
mutated or functionally impaired p53 pathway, were completely insensitive to the drug. Finally, we also found that nutlin-
3a increased response of glioma cells to radiation therapy. The results provide a basis for the rational use of MDM2
antagonists as a novel treatment option for glioblastoma patients.
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Introduction
The protein p53 is a key regulator of the multiple cellular
processes, and depending on the cell type and other factors p53
activation can result in apoptosis, reversible (quiescence) and
irreversible cell cycle arrest [1,2]. p53 is negatively regulated by
MDM2 through different mechanisms in coordination with
HDMX (MDM4). MDM2 binds the transcription domain of
p53 and blocks its ability to activate gene transcription [3,4].
MDM2 also functions as an E3 ligase, mediating the ubiquitina-
tion and proteasome degradation of p53 [4,5,6]. In addition,
MDM2 can also promote nuclear export of p53 and inhibit its
acetylation [7]. Accordingly, MDM2 inhibition could be an
effective approach toward enhancing cancer therapy. Nutlins,
potent and selective small-molecule antagonists of MDM2, have
been shown to activate the p53 pathway in wild-type p53 cell lines
of diverse human malignancies both in vitro and in vivo [8,9].
Nutlins bind to the p53-binding pocket in the MDM2 protein, thus
inhibiting the binding of p53 and activating the p53 pathway in
cancer cells with wild-type p53, including solid tumors [10,11] and
hematological malignancies [12,13,14,15]. Nutlin-3a, the active
enantiomer of nutlin-3, has been shown to inhibit growth of p53
wild-type human tumors grown as xenografts in nude mice and to
induce apoptosis and cell cycle arrest in cancer cell lines that
express wild-type p53 [16,17,18].
Glioblastoma multiforme (GBM) is the most common and most
malignant primary brain tumor in adulthood [19,20]. Despite
treatment efforts including new technological advances in
neurosurgery, radiation therapy, and clinical trials with novel
therapeutic agents, the vast majority of glioma patients die within
2 years of diagnosis [21,22,23]. Different molecular alterations in
critical regulatory genes that promote tumor growth, invasion, and
resistance to apoptotic stimuli have been identified in human
glioblastomas and related to both gliomagenesis and response to
therapy [20,24,25,26]. In this sense, the recent TCGA pilot
project showed that TP53 mutations or homozygous deletion and,
MDM2 amplification were observed in 35% and 14% of
glioblastoma patients, respectively. In addition, amplification of
HDMX gene has been observed in only 4% of analyzed samples
[25]. As such, increasing attention has focused on developing new
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in gliomas in order to improve treatment responses [27].
The purpose of this study is to investigate the antitumor activity
of nutlin-3a in glioblastoma cell lines and primary cultured
glioblastoma cells. We demonstrate that nutlin-3a induces p53-
dependent apoptosis and cellular senescence in wild-type p53
glioma cell lines and primary glioblastoma cultures. Furthermore,
we show that nutlin-3a fails to induce apoptosis and cell cycle
arrest in glioblastoma cells with mutant p53. Finally, we also found
that nutlin-3a enhanced radiation response of glioma cells. Taken
together, the results of the present study suggest that MDM2
antagonists may provide a novel treatment option for glioblastoma
patients.
Results
Nutlin-3a induces cell cycle arrest and apoptosis in wild-
type p53 U87MG but not in p53-mutated T98G cells
To determine whether nutlin-3a induced a decrease in cell
viability, U87MG (wild-type p53) and T98G (mutant p53, as
negative control) human glioblastoma cell lines were evaluated.
Both cell lines were incubated either with nutlin-3a at different
final concentrations from 0.5 to 20 mM or with DMSO vehicle
(untreated control) for 48 h and 96 h, and cell viability was
assessed by MTT assay. No significant changes in cell viability
were observed in either cell line after 48 hours of nutlin-3a
incubation (data not shown). However, as shown in Figure 1A,
96 hours of incubation with nutlin-3a resulted in a dose-dependent
reduction in cell viability in the wild-type p53 U87MG cell line
whereas no significant decrease in cell viability was observed in
mutant-p53 T98G cell line (Figure 1A). In addition, treatment
with nutlin-3a resulted in a dose-dependent accumulation of p53
protein in these cells with a maximum at 10 mM (Figure 1B).
Indeed, p53-induction did not increase after treatment with nutlin-
3a at a final dose of 20 mM (data not shown). Mutant-p53 T98G
did not induce p53 after nutlin-3a incubation at different doses
(Figure 1B). In light of these results, we carried out subsequent
experiments with nutlin-3a at a final dose of 10 mM.
To further investigate the effect of nutlin-3a on cell viability,
U87MG and T98G cell lines were incubated either with nutlin-
3a at a final concentration of 10 mM or with DMSO vehicle
(untreated control), and viable cells were counted with trypan
blue exclusion assay at different times from 24 to 96 hours. In
U87MG cells, a decrease in the number of viable cells was
found 24 hours after incubation when compared to controls. A
slight increase in the number of cells was observed 48 hours
after treatment; the number of cells then remained stable from
48 to 96 hours (Figure 1C), suggesting that the drug had a
cytostatic effect on these cells. No effect on cell counting was
observed in T98G mutant-p53 cell line (Figure 1D). To further
investigate the effects of nutlin-3 on glioma cells, induction of
apoptosis was assessed by annexin V staining positivity. As
shown in Figure 1E, U87MG cells showed a time-dependent
increase of apoptosis induced by nutlin-3a (from 3.3 to 27% at
24 and 96 hours, respectively) when compared to DMSO
vehicle control, whereas no apoptosis was observed in T98G
cells, suggesting resistance to MDM2 inhibition in glioblastoma
cell lines with mutant p53.
To better characterize the mechanisms by which MDM2
antagonists induced p53-dependent apoptosis, changes in overall
apoptosis expression profile by RT-MLPA were analyzed in both
glioblastoma cell lines. Upon incubation with nutlin-3a for 48 and
96 hours, U87MG cells showed changes in the mRNA profiles of
p53-target genes PUMA and Survivin. Interestingly, an important
decrease in the levels of Survivin mRNA was observed together
with an accumulation of PUMA mRNA. Another p53-target gene,
the pro-apoptotic Bcl-2 family member Noxa, showed no increase
in response to nutlin-3a in glioma cell lines (Figure 1F and Figure
S1). These data demonstrate the ability of nutlin-3a to activate the
intrinsic apoptotic pathway by a p53-dependent mechanism in a
glioma cell line that expresses wild-type p53. By contrast, no
changes in mRNA profile were observed in the mutant-p53 T98G
cell line either at 48 or 96 hours after MDM2 inhibition (Figure 1F
and Figure S1).
Results obtained in the mRNA pattern were verified by analysis
of protein expression with Western blot. p53, p21, MDM2,
PUMA and cleaved caspase 3 proteins increased upon treatment
with nutlin-3a in U87MG cells, whereas Survivin protein
expression markedly decreased (Figure 1G). T98G cells showed
basal mutant p53 protein expression with a slight induction after
nutlin-3a exposure. Accordingly, neither reduction of Survivin
expression nor induction of p21, MDM2, PUMA or cleaved
caspase 3 proteins was observed after MDM2 inhibition in the
mutant p53 glioma cell line (Figure 1G).
Nutlin-3a induces p53-dependent irreversible cell-cycle
arrest and senescence in U87 cell line
Despite weak apoptotic changes observed 24 hours after nutlin-
3a incubation, cell growth of p53 wild-type glioblastoma cell line
was significantly depressed at that time. To clarify this discor-
dance, the effects of nutlin-3a on cell-cycle distribution were
evaluated by flow cytometry at different treatment times, from 24
to 96 hours. Nutlin-3a effectively arrested cell-cycle progression in
U87MG cells 24 hours after treatment, depleting the S-phase
compartment (from 21% to 3%) and increasing the G0/G1 (from
63% to 80%) and G2/M (from 12% to 17%) phase compartments.
Cell-cycle arrest persisted 96 h after nutlin-3a incubation
(Figure 2A), suggesting that nutlin-3a might impede cell cycle
progression at both the G1/S and G2/M checkpoints in wild-type
p53 U87MG cell line. T98G mutant-p53 cells showed no
significant differences regarding cell cycle profile when comparing
controls (DMSO vehicle) to treated cells (Figure 2B). In addition,
nutlin-3a induced p21 expression, an important mediator of p53-
dependent cell cycle arrest, 24 h after incubation, and it persisted
96 hours after treatment (Figure 2C).
To elucidate whether nutlin-3a induces permanent cell cycle
arrest and senescence, or reversible cell cycle arrest in glioblastoma
cells, the ability of resume proliferation was evaluated. U87MG
glioma cell line was incubated with nutlin-3a or DMSO vehicle
(untreated control) for 4 days and then the cells were washed to
remove nutlin-3a and incubated for additional 6 days in fresh
media. After removal of the drug, glioma cells barely resumed
proliferation (Figure 2D). We then evaluated whether U87MG
treated cells showed features of senescence by staining them with
SA-bGal. Nutlin-3a-treated glioma cells acquired an enlarged and
flat morphology and expressed the senescence-associated SA-bGal
after 4 days of nutlin-3a-incubation (see square 4d in Figure 2E),
which persisted upon removal the drug (see square 4d+wash 6d in
Figure 2E). Furthermore, persistent induction of p21 protein was
also observed, thus suggesting that cell-cycle arrest exceeded the
duration of treatment (Figure 3C). Additionally, irreversible cell
cycle arrest by nutlin-3a was also confirmed by colony forming
assay. U87MG cells presented a significant decrease in the
capacity to form colonies upon removal of nutlin-3a when
compared to control (Figure 2G). Indeed, most of the remaining
cells exhibited a large/flat morphology and were SA-bGal-positive
(see square *4d+wash 6d in Figure 2E). Induction of p53 can cause
apoptosis, reversible cell cycle arrest (quiescence), and irreversible
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have demonstrated that when the cell cycle is blocked, activation
of mTOR is required for induction of senescence. Thus, in spite of
its ability to induce cell cycle arrest, p53 can act as a suppressor
of cellular senescence when inhibits mTOR pathway [28,29,
30,31,32,33]. To further evaluate whether senescence induced by
nutlin-3a in glioma cells is depending on mTOR signaling, we
evaluated activity of mTOR pathway after treatment. Western
blot analysis of S6 phosphorylation protein suggested that mTOR
pathway remains active after nutlin-3a in glioma cells (Figure 2F).
Taken together, these results confirm that nutlin-3a induces
senescence in U87MG cells and suggest that it might be dependent
on mTOR pathway activity.
Silencing of p53, but not overexpression of Survivin,
suppresses nutlin-3a cytotoxicity in wild-type p53 U87
cell line
Owing to the potential antiapoptotic role of Survivin, we asked
whether overexpression of exogenous Survivin would protect
glioma cells from nutlin-induced apoptosis. Western analysis
showed substantial elevation of the basal Survivin levels in the
cells transfected with Survivin expression construct compared with
the vector controls (Figure 3A). Unexpectedly, restoration of
Survivin did not prevent p53, p21, MDM2, Puma and cleaved
caspase 3 protein induction after nutlin-3a incubation (Figure 3A).
Furthermore, ectopic overexpression of Survivin and treatment
with nutlin-3a resulted in a non-significant reduction of apoptosis
induction (6.8% in pcDNA-empty and 8.55% in pcDNA-Survivin-
transfected DMSO control cells, and 21.2% in pcDNA-empty and
24.6% in pcDNA-Survivin-transfected nutlin-3a treated cells)
(Figure 3B). No changes in cell cycle profile were observed
between pcDNA-empty and pcDNA-Survivin transfected cells
after nutlin-3a incubation (data not shown).
To investigate whether knocking down p53 rendered U87MG
cells resistant to nutlin-3a apoptosis and cell-cycle arrest induction,
cells were transfected with p53 siRNA (or control siRNA) and
treated with nutlin-3a as described above. Immunoblotting of
U87MG cells demonstrated that p53, p21 and MDM2 were
induced after 24, 48 and 72 hours of nutlin-3a treatment or after
transfection with control siRNA, whereas they decreased to near
baseline levels after p53 siRNA. In addition, MDM2 antagonists
and p53 siRNA resulted in reduced PUMA and cleaved caspase-3
induction when compared with cells transfected with control
siRNA (Figure S2A). As expected, p53 siRNA followed by nutlin-
3a treatment resulted in maintenance of cell viability (Figure S2B)
and reduced apoptosis induction when compared with control
siRNA (Figure S2C).
Nutlin-3a induces p53-dependent apoptosis, cell cycle
arrest and senescence in p53 wild-type primary cultured
glioblastoma cells
To further analyze the ability of nutlin-3a to induce apoptosis in
glioblastoma, primary cultured glioblastoma cells obtained from
patients and grown in culture for a very short period of time were
used. Primary cultured glioblastoma cells from nine different
patients were incubated with nutlin-3a for 48 and 96 hours. Short-
time incubation with MDM2 inhibitor did not demonstrate
changes in the number of cells between control and treated
cultures (data not shown). As shown in Figure 4A, a significant
decrease (Student t test, p=0.005) in the number of cells was
observed in all but two patients (#23 and #35) treated with
nutlin-3a when compared to controls. To further evaluate nutlin-
3a’s effect, induction of apoptosis by surface annexin V positivity
was analyzed in all but one patient (#17, due to a lack of cells).
Cell viability decreased from 91%62% to 78%610% (Student t
test, p=0.012) after incubation with nutlin-3a for 96 hours in
wild-type p53 primary culture. There were important case-to-case
differences in apoptosis induction after nutlin-3a incubation
(Figure 5B). However, in all glioblastoma patients with wild-type
p53 (Table 1), nutlin-3a had pro-apoptotic and anti-proliferative
effects (Figure 4A and B). Two patients (#23 and #35) presented a
very low non-significant apoptosis induction after MDM2
inhibition when compared to controls (Figure 4B). In addition,
one patient with no apoptosis induction upon nutlin-3a incubation
had a p53-mutation (R306X in patient #23), and patient #35
carried a TP53 polymorphism (R72P). Variant p53-P72 has
previously been described as having a weaker apoptotic potential
in lung cancer cells. However, it is not yet known how universal
these functional differences between the two variants might be in
different cell types, nor whether they are relevant in vivo [34,35]. In
addition, response to MDM2-inhibitors was independent of
MGMT promoter methylation status (Table 1). Together, the
present results confirm the hypothesis that inhibition of MDM2-
p53 binding in primary cultured glioblastoma cells with functional
p53 pathway induces apoptosis. Additionally, primary cultured
glioblastoma cells with mutant p53 are resistant to nutlin-3a
apoptosis induction.
To further analyze p53-dependent apoptosis in primary
cultured glioblastoma cells, changes in apoptosis-related gene
expression profile were evaluated by RT-MLPA in six samples.
Three patients were excluded from the analysis due to low RNA
yield. Nutlin-3a treatment for 48 and 96 hours induced changes in
PUMA, Noxa and Survivin gene expression in wild-type p53 samples.
The most noteworthy result was the decrease in Survivin mRNA
expression observed in these patients with a reduction of cell
Figure 1. Effect on cell viability and apoptosis of MDM2 antagonists on glioblastoma cell lines. A, viability of U87MG (p53 wild-type) and
T98G (p53-mutant, negative control) cell lines was assessed by MTT reduction at 96 hours of incubation with either different nutlin-3a concentrations
or DMSO treatment (vehicle control). Results are expressed as % compared with DMSO-treated controls and represented as the mean 6 standard
deviation (sd) for three distinct experiments. U87MG [closed squares] and T98G [closed triangles]. B, cells were treated with nutlin-3a (5 or 10 mM) or
DMSO (vehicle control) for 24 hours, and then lysed and analyzed by Western blot as described in ‘‘Patients, materials and methods’’. Treatment with
nutlin-3a resulted in a dose-dependent accumulation of p53 protein in U87MG cells whereas no changes were observed in p53-mutant T98G cell line;
C and D, cells were treated with nutlin-3a (10 mM) or DMSO (vehicle control); cells were counted with trypan blue exclusion assay at the indicated
days. Points, average of three independent assays expressed as the mean 6 sd. (C: U87MG; D: T98G); E, time course of nutlin-3a induced apoptosis.
U87MG and T98G glioblastoma cell lines, were incubated for 24 to 96 hours with either 10 mM nutlin-3a or DMSO (vehicle control). Apoptosis was
measured by surface Annexin V staining and flow cytometry as described in ‘‘Patients, materials and methods’’. Apoptosis values of treated cells are
represented with respect to the DMSO control (vehicle controls). Data are shown as the mean of at least three independent assays 6 sd. ** p,0.01,
statistical significance (Student’s t test); F, glioblastoma cell lines U87MG and T98G were treated with 10 mM nutlin-3a or DMSO vehicle for 48 and
96 hours. Expression of apoptosis-related genes was analyzed by RT-MLPA as described in ‘‘Patients, materials and methods’’. Quantification of mRNA
(y axis) is expressed as the base-2 logarithm (log2) of the fold induction relative to DMSO-vehicle treated cells. G, effect on p53, MDM2, p21, Survivin
and PUMA proteins was evaluated 96 hours after nutlin-3a exposure. Cells were treated with nutlin-3a, and then lysed and analyzed by Western blot
as described in ‘‘Patients, materials and methods’’. Immunoblots are representative of at least three independent experiments. CT: DMSO vehicle
control; N: 10 mM nutlin-3a.
doi:10.1371/journal.pone.0018588.g001
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18588Figure 2. Nutlin-3a induced cell cycle arrest and cellular senescence in U87MG cells. A and B, glioma cell lines (A: U87MG; B: T98G) were
treated either with nutlin-3a or DMSO (vehicle control) for 24 to 96 hours, and cell cycle profile was measured by flow cytometry. Columns, average of
three independent determinations; C, time-course of p21 protein expression in U87MG cells after nutlin-3a incubation for 1 to 4 days; 10 days
showed p21 protein expression on day six after removal of nutlin-3a (day 10 after cells were plated). Immunoblots are representative of at least three
independent experiments; D, U87MG cells were treated with nutlin-3-a for 4 days, then washed to remove the drug and incubated for additional six
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#14, 17, 19 and 33) (Figure 4C and Figure S3). An increase in
PUMA mRNA expression was found in all but one patient
(patients #14, 19 and 33). In addition, an increase in Noxa mRNA
expression was also observed in patients #14 and #17.
To verify changes observed in the pro-apoptotic mRNA
expression profile, primary cultured glioblastoma cells were
analyzed by Western blot for expression levels of p53, MDM2,
p21, PUMA, Noxa and Survivin proteins (Figure 4D). p53 and
p21 protein accumulation was observed in primary cultured
glioblastoma cells with wild-type p53 after MDM2 inhibition.
Regarding MDM2, all patients with p53 wild-type resulted in
nutlin-3a induced protein expression (Figure 4D). Expression of
baseline MDM2 protein was observed in 3 out of 6 patients with
wild-type p53 (patients #3, 17 and 20) which resulted in higher
nutlin-3a apoptosis induction (Figures 4B and 4D). A decrease in
Survivin protein expression was observed in all patients with
nutlin-3a-induced apoptosis, consistent with the low levels of
Survivin mRNA previously found at RT-MLPA. Regarding Noxa
protein expression, 5 out of 6 patients with p53 wild-type
demonstrated induction after MDM2 inhibition (patients #3,
14, 19, 20 and 33), consistent with results found at the mRNA
level. Finally, an increase in PUMA protein expression was
observed in 4 out of 6 patients with wild-type p53 after nutlin-3a
incubation (patients #14, 19, 20 and 33). In this case, protein
results were also consistent with those found at the mRNA level
(Figure 4C and 4D). No changes in Survivin, PUMA or Noxa
mRNA expression were observed in p53-mutant patients #23 and
#35, resistant to MDM2 inhibition (Figure 4C and Figure S3). At
the protein level, both patients showed high baseline expression of
p53 protein without induction after drug treatment. An increase of
Survivin protein expression was also observed upon MDM2
inhibition. In addition, patient #23 exhibited an increase in p21
protein expression after nutlin-3a treatment. Changes in other p53
target proteins were not observed (Figure 4D). Patient #35,
carrying a p53 polymorphism [34] that could partially explain the
lack of apoptosis induction, exhibited resistance to nutlin-3a
treatment.
To evaluate whether nutlin-3a induced senescence in wild-type
p53 primary glioblastoma cultures, cells were treated with either
nutlin-3a or DMSO (vehicle control), and the expression of
senescence marker SA-bGAL was evaluated 4 days after
incubation. Upon nutlin-3a incubation the percentage of positive
cells increased when compared to DMSO vehicle, from 28%69%
to 82%68%, respectively (Student t test, p,0.001) (Figure 4E).
Nutlin-3a enhances radiation response in wild-type p53
glioma cells
It has been shown previously that cells in G1 are approximately
twice as radiosensitive as cells in S-phase [36], and therefore we
considered the possibility that the cell cycle arrest that we observed
in wild-type glioma cells might also lead to increased radiosensitiv-
ity. Thus, we performed in vitro clonogenic assays for glioma cells
after 2 h pre-treatment with nutlin-3a (0.5 mM) or DMSO (vehicle
control)followedbyexposuretoX-rayirradiationat0,2,46or8Gy
(Clinac600CD,M/SVarianAG,USA).Pre-treatmentwithnutlin-
days in fresh media. After removal of the drug, cells were trypsinized and counted. Results are shown as mean 6 sd. of at least three independent
experiments; E, representative photomicrographs of U87MG cells stained with SA-bGal after treatment with DMSO vehicle control (Upper left
photomicrograph) or with 10 mM nutlin-3a for 4 days (Upper right photomicrograph). Then, the drug was washed out and cells were stained for SA-
bGal after incubation for additional 6 days (Lower photomicrograph); F, effect on p53, p21, pS6 and S6 proteins was evaluated 48 hours after nutlin-
3a exposure by Western blot as described in ‘‘Patients, materials and methods’’; G, representative photomicrographs of colony formation assay.
Colonies were counted on day six after nutlin-3-a was removed (day 10 after cells were plated). The number of colonies was scored in three
independent experiments and was represented as surviving fraction relative to DMSO vehicle-treated controls 6 sd.
doi:10.1371/journal.pone.0018588.g002
Figure 3. Ectopic overexpression of Survivin fails to suppress nutlin-3a cytotoxicity in wild-type glioma cells. A, Immunoblots were
performed 48 hours after transfection and 72 hours after treatment either with DMSO or nutlin-3a. Restoration of Survivin did not prevent p53,
MDM2, p21, PUMA and cleaved Caspase 3 induction after treatment with nutlin-3a; B, Induction of apoptosis in DMSO (CT) and nutlin-3a (N) treated
cells 48 hours after transfection either with empty pcDNA3 (empty) or plasmid expression vector pcDNA3-Survivin (survivin) and 72 h after treatment.
Apoptosis was measured by surface Annexin V staining and flow cytometry as described in ‘‘Patients, materials and methods’’. Average of a total of
three independent assays 6 sd. empty: empty vector; Survivin: Survivin-expressing vector.
doi:10.1371/journal.pone.0018588.g003
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significantly more radiosensitive (comparison of surviving fraction
values; P,0.0001, log-rank scale) (Figure 5A). As expected from our
earlierdata,nutlin-3atreatmenthad nosignificanteffect onmutant-
p53 glioma cells. In addition, incubation of U87MG cells with
nutlin-3a (0.5 mM) in combination with cisplatin (2 mM) signifi-
cantly decreased cell viability when compared with each treatment
alone (Student t test, p,0.05) with a combined index of 0.16,
suggestive of synergistic effect (Figure 5B). No effect was observed
when we combined nutlin-3a with temozolomide at different doses.
Finally, we also evaluated the effect of nutlin3-a on normal brain
cells. Normal human astrocytes (NHA) were incubated with nutlin-
3a at a final concentration of 10 mM and we observed a decrease in
cell viability in MTT assay (100% cell viability in DMSO vehicle
and 40% in nutlin-3a after 96 h of incubation). A slight induction of
apoptosiswasalsoobservedinNHAwith non-significantdifferences
when compared with mutant-p53 T98G cell line (negative control)
(Figure 5C). In addition, western-blot analyses demonstrate an
increase in p53, MDM2 and p21 protein expression (Figure 5D).
The discordance observed when comparing the decrease in cell
number assessed by MTT and apoptosis induction together with
p21 induction strongly suggests that nutlin-3a mainly induced cell
cycle arrest but not apoptosis in NHA. These results agree with
previous data reported that MDM2 antagonists induce reversible
cell cycle arrest but not cell death in normal cells [8] and indicate
that wild-type-p53 glioblastoma cells are more sensitive to nutlin-3a
treatment than NHA.
Discussion
In this study, we show that nutlin-3a effectively stabilizes and
activates p53 in glioblastoma cell lines as well as in primary
glioblastoma cultured cells with wild-type TP53, leading to
induction of p53-dependent cell-cycle arrest and apoptosis. In
addition, our results also indicate that in wild-type p53 glioblastoma
cells, cell cycle arrest is the primary response to MDM2 inhibition,
whereas induction of apoptosis varies substantially. In fact, these
findings are in line with previous reports in which the antitumor
activity of nutlin-3a was demonstrated in a variety of wild-type p53
cancer cells of both solid tumors [10,11,15] and hematological
malignancies [12,13,14]. Overall, the most common effect in solid-
tumors is cell cycle arrest. Nutlin-induced apoptosis is more likely a
reflection of a cell’s ability to undergo p53-dependent apoptosis
[17,18]. Indeed, cancer cell lines can differ significantly in their
apoptotic response to similar levels of p53 activation. Accordingly,
the results of the present study suggest that in glioblastoma cells
nutlin-3a primarily induces p53-dependent cell-cycle arrest and
senescence, and to a lesser extent, apoptosis.
Our study provides direct evidence that both cell cycle arrest
and senescence, and apoptosis induced by nutlin-3a are due to
activation of the p53 pathway. p53 promotes G1 cell arrest
through its ability to induce p21 expression [37], and p53 and p21
levels are increased by nutlin-3a treatment in wild-type p53
glioblastoma cells. In addition, our experiments show that
knocking down p53 expression using siRNA restores cell viability
and decreases p21 to normal levels. Moreover, p53 knockdown
also diminishes apoptosis, and proapoptotic PUMA and cleaved
caspase 3 protein induction, thus demonstrating that the nutlin-
induced cell cycle arrest and apoptosis observed in glioblastoma
cells are p53-dependent. The fact that p53-mutant T98G cells and
glioblastoma primary cultures are insensitive to nutlin-3a further
reinforces the above-mentioned concept.
Interestingly, our results show that MDM2 inhibition induces
cellular senescence in p53 wild-type glioblastoma cells. Thus, wild-
type p53 glioblastoma cells barely resume their proliferative
Table 1. Patient characteristics.
Patient id. Age Diagnosis W.H.O. grade p 53 status
MGMT promoter
methylation status EGFRvIII mutation
02 65 GBM IV Wt Unmethylated +
03 74 GBM IV Wt Methylated Nd
14 49 GBM IV Wt Unmethylated Nd
17 65 GBM IV Wt Nd Nd
19 77 GBM IV Wt Methylated Nd
20 76 GBM IV Wt Unmethylated -
23 72 GBM IV Mutated Nd -
33 69 GBM IV Wt Unmethylated -
35 45 GBM IV P Methylated +
GBM: glioblastoma multiforme; Wt: wild-type; P: Polymorphism R72P; Nd: not done.
doi:10.1371/journal.pone.0018588.t001
Figure 4. Effects of MDM2 antagonists on primary cultured glioblastoma cells. A, cell count on nine primary cultured glioblastoma cells
treated with DMSO (vehicle control) (%) or treated with 10 mM nutlin 3-a (&); Columns, average of two independent assays; bars sd. ** p,0.01,
statistical significance of nutlin-3a treated cells with respect to the untreated controls (Student’s t test). B, effect of nutlin-3a on apoptosis induction
in eight primary cultured glioblastoma cells treated with DMSO (vehicle control) (%) or treated with 10 mM nutlin 3-a (&); Columns, average of two
independent assays; Apoptosis was measured by surface Annexin V staining and flow cytometry as described in ‘‘Patients, materials and methods’’.
Columns, average of two independent assays; bars sd. ** p,0.01, statistical significance of nutlin-3a treated cells with respect to the untreated
controls (Student’s t test); C, expression of p53 target genes was analyzed by RT-MLPA as described in ‘‘Patients, materials and methods’’. The results
are shown as logarithmic fold induction relative to untreated cells; D, effect on p53, MDM2, p21, Puma, Noxa and Survivin was evaluated 48 hours
after nutlin-3a exposure by Western blot. Cells were treated with nutlin-3a, and then lysed and analyzed by Western blot as described in ‘‘Patients,
materials and methods’’ (CT: DMSO vehicle control; N: 10 mM nutlin-3a); E representative photomicrographs of three glioblastoma cultured cells
stained with SA-bGal after treatment with 10 mM nutlin-3a (N) or with DMSO vehicle control (C) for 4 days.
doi:10.1371/journal.pone.0018588.g004
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colonies, acquiring an enlarged and flat morphology with SA-
bGal-positive expression upon nutlin-3a removal. Senescence
induction by nutlin-3a has been previously reported in fibroblasts
and fibrosarcoma cells [28], T-cell leukemia cells [29] and
neuroblastoma [30]; however, to our knowledge, this is the first
time to report that nutlin-3a induces senescence in glioma cells.
Although p53 has been regarded as a canonical inducer of
senescence [2], recent studies have found that p53 could also
negatively regulate senescence. Mechanism undergone senes-
cence-induced by nutlin-3a may be dependent on both p53
induction of cell cycle arrest and p53 regulation of mTOR
pathway. Indeed, the principal role of p53 is to promote cell cycle
arrest but the subsequent fate of the arrested cells may be
dependent on its effect on mTOR signaling [29,30,31,32,33].
According to the above-mentioned mechanisms, our results
suggest that nutlin-3a induces senescence in p53 wild-type
glioblastoma cells by its failure to inhibit the mTOR pathway.
In the present study, nutlin-3a was found to down-regulate
Survivin in glioma cell lines and primary glioblastoma cells with
wild-type p53. Survivin, a member of the inhibitor of apoptosis
protein (IAP) family, functions as a key regulator of mitosis and
programmed cell death. Survivin, in cooperation with other IAP
molecules (such as hepatitis B X-interacting and X-linked IAP
proteins), selectively blocks apoptosis at the level of effector
caspases [38,39]. Survivin gene expression is transcriptionally
repressed by wild-type p53, and down-regulation of Survivin has
been reported to induce a block of cell entry into S phase and cell-
cycle arrest in G2/M phase
35. Uchida et al.[40] reported that
siRNA against Survivin was able to induce apoptosis and suppress
cell growth both in vitro and in vivo in U251 glioma cells.
Surprisingly, in our study, ectopic overexpression of Survivin failed
to rescue U87MG cells from the cytotoxic effects of MDM2
inhibition. Previous studies have demonstrated that ectopic
overexpression of Survivin resulted in reduction of cell death in
U87MG cells upon TRAIL-quercetin incubation[41]. The results
of our study suggest that upon nutlin-3a incubation, down-
regulation of Survivin might be redundant with other induced
changes, and its overexpression is unable by itself to abolish cell
cycle arrest and apoptosis in U87MG cells.
Finally, we found that nutlin-3a enhanced radiation response of
wild-type p53 glioma cell lines. Pre-treatment with nutlin-3a
induces cell cycle arrest making glioma cells more sensitive to
radiation therapy. Further studies are needed to better elucidate
Figure 5. Nutlin-3a enhances radiation response in wild-type p53 glioma cells. A, clonogenic assays of p53-wild-type U87MG cells after 2 h
pre-treatment with DMSO (vehicle control) (¤) or nutlin-3a (0.5 mM) (%)followed by exposure to X-ray irradiation at 0, 2, 4 6 or 8Gy; The number of
colonies were represented as surviving fraction. Data are shown as the mean of at least three independent experiments; B, effect on cell viability
assessed by MTT assay of p53-wild-type U87MG cells after being treated with nutlin-3a 0.5 mM (N), 2 mM cisplatin (CP) and both (NCP); or being
treated with 1 mM temozolomide (T) and both (NT). Data are shown as the mean of at least three independent experiments 6 sd. * p,0.05,
** p,0.0001, statistical significance (Student’s t test); C, time course of nutlin-3a induced apoptosis. normal human astrocytes (NHA), were incubated
for 24 to 96 hours with either 10 mM nutlin-3a or DMSO (vehicle control). Apoptosis was measured by surface Annexin V staining and flow cytometry
as described in ‘‘Patients, materials and methods’’.). Data are shown as the mean of at least three independent assays 6 sd. ** p,0.01, statistical
significance (Student’s t test); D, effect on p53, MDM2, and p21 proteins of nutlin-3a incubation in NHA. Cells were treated with nutlin-3a, and then
lysed and analyzed by Western blot as described in ‘‘Patients, materials and methods’’ (CT: DMSO treated vehicle control; N: 10 mM nutlin-3a).
doi:10.1371/journal.pone.0018588.g005
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along with the demonstration of pleiotropic activities of nutlin-3a
by inducing cell cycle arrest and senescence, and apoptosis in
glioblastoma cells make MDM2 inhibitors particularly attractive
for the treatment of glioblastoma patients.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all patients in
accordance with the Hospital de Bellvitge Ethics Committee. The
study was approved by the Hospital de Bellvitge Ethics Committee.
Cell lines and primary cultured glioblastoma cells
U87MG (TP53 wild-type) and T98G (TP53 mutant, M237I)
glioma cell lines were obtained from the American Type Culture
Collection and cultured with DMEM with 10% fetal calf serum
(FCS) supplemented with L-glutamine (2 mM) and penicillin-
streptomycin (100 U/ml-100 mg/ml). Normal human astrocytes
(NHA) were obtained from Lonza (Lonza Cologne AG, Germany)
and were cultured with astrocyte basal medium with 10% fetal
bovine serum supplemented with 0.1% gentamycin sulfate-
amphotericine B, 0.1% ascorbic acid, 0.25% insulin, 1% L-
glutamine and 0.1% hEGF. For primary cultured glioblastoma
cells, tumor samples were obtained from nine patients undergoing
surgical treatment for a glioblastoma multiforme (W.H.O grade
IV [20]) at the neurosurgical department of the Hospital de Bellvitge,
and these were processed within 1 h after resection. Table 1
provides details of patients whose tumors were assayed in this
study. The tumor fragment was rinsed with Hank’s Balanced Salt
Solution (HBSS) and mechanically dissociated into pieces of ,1–
5m m
3. Tissue minced pieces were incubated with collagenase I at
a final concentration of 200 U/ml in HBSS for 1 hr at 37uC with
constant vigorous agitation. The cellular suspension was then
washed with DMEM supplemented with 10% heat-inactivated
FCS, 2 mM glutamine, and 100 U penicillin and 100 mg/ml
streptomycin (culture growth medium). After centrifugation, a thin
red strip at the top of the cell pellet corresponding to the remaining
erythrocytes was delicately discarded and the pellet was resus-
pended in culture growth medium. The cellular suspension was
plated in 60 mm tissue culture plates and maintained at 37uCi na
humidified atmosphere containing 5% carbon dioxide. Cell
cultures were subsequently split 1:2 when confluent and
experiments were done before pasages 3–5. All experiments
performed with primary cultured glioblastoma cells were repeated
at least twice in triplicate.
Cell viability analysis
The viability of cultured cells was determined by assaying the
reduction of MTT [3-[4,5-dimethylthazol-2-yl]-2,5-diphenyl tet-
razolium-Bromide] (Sigma Chemical Co.) to formazan. Glioma
cell lines were plated in a 96-well plate, 5000 cells/well in a final
volume of 100 ml. Cultures were treated with DMSO vehicle
(untreated control) or increasing concentrations of nutlin-3a (0.5–
20 mM, kindly provided by Dr. L. Vassilev, Hoffmann-La Roche)
and evaluated at different times from 24 to 96 hours. After the
indicated treatment, cells were incubated for 2 h at 37uCi n
DMEM containing 10 mM MTT (diluted in PBS). The blue MTT
formazan precipitate was then dissolved in 100 ml of DMSO, and
the absorbance was measured at 540 nm on a multiwell plate
reader.
Cell viability was also assessed by counting the adherent cells
with or without treatment (DMSO vehicle control). Glioma cell
lines and primary cultured glioblastoma cells were seeded in
culture growth medium and incubated with nutlin-3a or DMSO
vehicle (untreated control). Experiments were performed at ,70%
cell confluence. For cell counting, attached cells were trypsinized
at different times from 24 to 96 hours after treatment. Cell
counting was determined by trypan blue exclusion assay in a
Neubauer chamber slide.
Analysis of apoptosis by flow cytometry
Apoptosis was measured by surface Annexin V staining and
flow cytometry. Treated and untreated cells were washed in
phosphate-buffered saline (PBS), trypsinized and incubated with
Annexin V–FITC (Bender MedSystems, Burlingame, CA) for 10
minutes. Cells were then diluted with Annexin-binding buffer to a
volume of 400 mL with propidium iodide. Samples were analyzed
with FACSCalibur and BD CellQuest Pro software (Becton
Dickinson, Mountain View, CA).
Cell cycle
After treatment, both floating and attached cells were fixed with
70% ethanol, resuspended in PBS/1%FBS, and treated with
RNase A. Propidium iodide was added to the cells and samples
were analyzed by flow cytometry in a FACSCalibur (Becton
Dickinson, Mountain View, CA). Cell-cycle profile analysis of the
DNA histograms of integrated red fluorescence was performed
with Modfit LT software (Verity Sotware, Inc, Topsham, ME).
RT-MLPA
RNA was analyzed by reverse transcriptase multiplex ligation-
dependent probe amplification (RT-MLPA) using SALSA MLPA
KIT R011 Apoptosis mRNA from MRC-Holland (Amsterdam,
The Netherlands) for the simultaneous detection of 38 messenger
RNA molecules [42]. Briefly, RNA samples (200 ng total RNA)
were first reverse-transcribed using a gene-specific probe mix.
After adding the probe mix, the resulting cDNA was allowed to
hybridize overnight at 60uC. After ligation of both probe pairs and
inactivation of ligase, PCR was performed in a volume of 50 ml
containing 10 ml of the ligation reaction mixture with one
unlabeled and one FAM labeled primer (33 cycles, 30 seconds at
95uC; 30 seconds at 60uC, and 1 minute at 72uC). Fragments were
separated by capillary electrophoresis on a 48-capillary ABI-Prism
3730 Genetic Analyzer (Applied Biosystems/Hitachi, Foster City,
CA). Peak area and height were measured using GeneScan
analysis software (Applied Biosystems). The levels of mRNA for
each gene were expressed as a normalized ratio of the peak area
divided by the peak area of a control gene, resulting in the relative
abundance of mRNAs in the genes of interest. The probe set
contains probes for mRNAs of 30 apoptosis-related proteins. Areas
were normalized to b2-Microglobuline.
Western blot analysis
Cells were lysed with Laemmli sample buffer, and equal amounts
of protein (50 mg) estimated by the BCA Protein Assay (Pierce,
Rockford, IL) were separated by electrophoresis on 8% or 12%
polyacrylamide gel and transferred to a PDVF membrane
(Amersham, Buckinghamshire, UK). After blocking for 1 hour with
5% dried skimmed milk in TBST, the blots were incubated
overnight at 4uC with the specific primary antibody. Primary
antibodies used were p53 (Neomarkers, Fremont, CA), p21 (Santa
Cruz Biotechnology, Santa Cruz, CA), MDM2, PUMA and Noxa
(Abcam, Cambridge, UK), Survivin (Novus Biologicals, Littleton,
CO), and S6, pS6 and cleaved Caspase 3 (Cell Signaling
Technology, Beverly, MA). Membranes were subsequently incubat-
ed with a secondary antibody conjugated to horseradish peroxidase
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(Amersham, Buckinghamshire, UK). Bands were analyzed by
densitometry and the numerical data were subjected to t test.
Detection of TP53 mutations
DNA was obtained using the AllPrep DNA/RNA Mini Kit
(Quiagen), and quantified with NanoDrop ND-1000 (Thermo
Fisher Scientific/ Waltham, MA). For the PCR reaction, specific
primers obtained from IARC TP53 Mutation Database website
(http://www-p53.iarc.fr) were used for each exon (exons 2 to 10).
Samples were purified with EZNA Cycle-Pure Kit (Omega Biotek)
and subsequently sequenced with big dye 3.1 PCR reaction, and
analyzed by means of capillary electrophoresis (Applied Biosys-
tem/Hitachi, Foster City, CA, USA). Finally, sequences were
evaluated with Gen Tool 1.0 (Biotools/Canada) and Multalin
5.4.1 software (http://www-archbac.u-psud.fr).
Methylation-specific PCR
Genomic DNA was isolated from frozen tumor using the AllPrep
DNA/RNA Mini Kit (Quiagen). DNA methylation status of CpG
islands at the enzyme O
6-methylguanine methyltransferase
(MGMT) promoter was determined by methylation-specific PCR
(MSP), as previously described [43], with some modifications.
Senescence associated b-galactosidase staining
Cells (5610
4) were plated in 6.0-cm-diameter plates and treated
with 10 mM nutlin-3a or DMSO (vehicle control). After for 4 days,
cells were washed to remove nutlin-3a and incubated for
additional 6 days in fresh media. Senescence b-galactosidase
(SA- bGal) staining was performed using the Senescence-bGal
Staining Kit (Cell Signaling Technology, Beverly, MA) following
the manufacturer’s instructions. Cells were considered positive
when the cytoplasm was stained with SA- bGal.
Colony formation assays
To assess clonogenic ability, cells were plated in six-well plates in
appropriate dilutions and treated with nutlin-3a or DMSO (vehicle
control). After for 4 days, cells were washed to remove nutlin-3a and
incubated for additional 6 days in fresh media. Then, colonies were
fixed with 2% ethanol and stained with 0.5% crystal violet. After
staining, colonies were counted with a cutoff of 50 viable cells, and
plating efficiency of cells was determined by calculating the ratio of
the number of colonies formed to the number of cells seeded in
DMSO-treated vehicle controls. Surviving fraction after treatment
was calculated, with plating efficiency taken into consideration,
according to a previous published protocol [44]. Each set of
experiments was done in triplicate.
Transfection and RNA interfering assays
U87MG cells were transiently transfected either with empty
pcDNA3 (negative control) or plasmid expression vector pcDNA3-
Survivin (kindly provided by Dr. D.C. Altieri, New Haven,
Connecticut) along with pcDNA-GFP using Amaxa Nucleofector
device (protocol U029; Amaxa Biosystems, Lonza). Transfection
efficiency was calculated by fluorescence microscopy and was always
above the 80%. Forty-eight hours after transfection, cells were
treated either with 10 mM nutlin-3a or DMSO vehicle (untreated
control) and evaluated for cell viability, apoptosis induction and
protein expression at 48 and 72 hours after treatment.
U87MG cells were suspended in 100 mLo fs o l u t i o nT( A m a x a )a n d
nucleofected either with 300 nmol/L of non-targeting negative-
control human small interference RNA (Negative Universal Control
siRNA, Invitrogen) or 300 nmol/L human p53 siRNA (TP53
UHS40367 siRNA, Invitrogen) with an Amaxa nucleofector device
(protocol X001; Amaxa Biosystems, Lonza). Six hours after
transfection, cells were treated either with 10 mM nutlin-3a or DMSO
vehicle (untreated control), and evaluated for cell viability, apoptosis
induction and protein expression at 48 and 72 hours after treatment.
Statistical analysis
Results are expressed as mean 6 standard deviation (SD) of
values obtained in at least three independent experiments.
Differences between samples were analyzed with Student t test.
Differences reaching a p value of 0.05 were considered significant.
All calculations were performed using the 14.0 SPSS software
package (SPSS Inc., Chicago, IL). The combination index (CI) was
calculated for a 2-drug combination using Biosoft CalculSyn
program (Fergurson, MO). A CI of 1 indicates an additive effect; a
CI above 1 an antagonistic effect; and a CI below 1, a synergistic
effect.
Supporting Information
Figure S1 Glioblastoma cell lines U87MG and T98G were
treated with 10 mM nutlin-3a for 48 hours and 96 hours.
Expression of apoptosis-related genes was analyzed by RT-MLPA
as described in ‘‘Patients, materials and methods’’. The results are
shown as fold induction relative to untreated cells.
(TIF)
Figure S2 Silencing of p53 suppresses nutlin-3a cytotoxicity in
wild-type p53 U87 cells. A, immunoblots demonstrating silencing
of p53 protein in U87MG cells 48 hours after transfection and
72 hours after nutlin-3a treatment. Knockdown of p53 prevent
U87MG cells to p53, p21, MDM2, Puma and cleaved caspase 3
proteins induction as well as Survivin down-regulation. Immuno-
blots are representative of at least three independent experiments.
B, U87MG cells transfected either with p53 specific siRNA or
negative-control siRNA and 6 hours later treated with nutlin-3a
(10 mM) or DMSO (vehicle control; ct). The number of viable cells
was counted with trypan blue exclusion assay at 48 and 72 hours.
Points, average of three independent assays expressed as the mean
6 sd. C, time course of nutlin-3a induced apoptosis in U87MG
cells 6 hours after transfection and 48 and 72 h after treatment.
Apoptosis was measured by surface Annexin V staining and flow
cytometry as described in ‘‘Patients, materials and methods’’.
Average of a total of three independent assays 6 sd.
(TIF)
Figure S3 Primary cultured glioblastoma cells were treated with
10 mM nutlin-3a for 96 hours. Expression of apoptosis-related
genes was analyzed by RT-MLPA as described in ‘‘Patients,
materials and methods’’. The results are shown as fold induction
relative to untreated cells.
(TIF)
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